Cytokinetics
CYTK
61.12
-0.23
-0.37%
Cytokinetics
US · CYTK
#1564 by market cap
Listed 1970
61.12
-0.23
-0.37%
Live - 5344 symbols - heartbeat 211s ago
· 2026-10-08 07:00
Pre-market
62.49
+2.24%
After-hours
61.12
0.00%
- Market cap
- 8.50B
- P/E (TTM)i
- -8.47
- P/Bi
- -48.97
- EPSi
- -6.54
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on CYTK?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 16 analysts
Buy
Avg price target
110.27 +80.4%
Price target rangecurrent 61.12
Low85.00
Avg110.27
High146.00
Buy 94%
Hold 6%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | Needham | -- | BUY | 112.00 |
| 2026-10-05 | H.C. Wainwright | -- | BUY | 140.00 |
| 2026-10-02 | Wells Fargo | -- | BUY | 105.00 |
| 2026-09-30 | H.C. Wainwright | -- | BUY | 140.00 |
| 2026-09-29 | Needham | -- | BUY | 112.00 |
| 2026-09-10 | RBC Capital | -- | BUY | 112.00 |
| 2026-09-01 | Truist Financial | -- | BUY | 112.00 |
| 2026-09-01 | RBC Capital | -- | BUY | 112.00 |
| 2026-08-31 | BofA Securities | -- | HOLD | 85.00 |
| 2026-08-31 | Evercore | -- | BUY | 100.00 |
| 2026-08-31 | H.C. Wainwright | -- | BUY | 140.00 |
| 2026-08-28 | Needham | -- | BUY | 112.00 |
| 2026-08-28 | Goldman Sachs | -- | BUY | 105.00 |
| 2026-08-28 | RBC Capital | -- | BUY | 112.00 |
| 2026-08-26 | Barclays | -- | BUY | 110.00 |
| 2026-08-20 | J.P. Morgan | -- | BUY | -- |
| 2026-08-14 | BofA Securities | -- | HOLD | 85.00 |
| 2026-08-14 | H.C. Wainwright | -- | BUY | 140.00 |
| 2026-08-13 | H.C. Wainwright | -- | BUY | 140.00 |
| 2026-08-13 | Barclays | -- | BUY | 110.00 |
| 2026-08-13 | J.P. Morgan | -- | BUY | 103.00 |
| 2026-08-12 | J.P. Morgan | -- | BUY | 103.00 |
| 2026-08-11 | Truist Financial | -- | BUY | 112.00 |
| 2026-08-07 | Piper Sandler | -- | BUY | 107.00 |
| 2026-08-07 | Truist Financial | -- | BUY | -- |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: UBS moved from Hold to Buy on 2026-06-29.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-06-29 | UBS | HOLD → BUY | 115.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-06 | After close | ±7.47% | -5.67% (in line) |
| 2026/Q1 | 2026-05-05 | After close | ±9.52% | -2.92% (in line) |
| 2025/Q4 | 2026-02-24 | After close | ±9.08% | -10.29% (beat) |
| 2025/Q3 | 2025-11-05 | After close | ±7.87% | +1.88% (in line) |
| 2025/Q2 | 2025-08-07 | After close | ±11.80% | -3.23% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±15.94% | -2.74% (in line) |
| 2024/Q4 | 2025-02-27 | After close | ±16.40% | -3.06% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±10.73% | +0.61% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±14.46% | +3.31% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±6.51% | -1.92% (in line) |
| 2023/Q4 | 2024-02-27 | After close | ±7.96% | -9.75% (beat) |
| 2023/Q3 | 2023-11-02 | After close | ±13.13% | +4.85% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:00:10 · For reference only, not investment advice and not tailored to your situation.